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Background: Schizophrenia, a severe psychiatric disorder, has a lifetime prevalence of 1%. The exact mechanisms
underlying this disorder remain unknown, though theories abound. Recent studies suggest that particular cell types
and biological processes in the schizophrenic cortex have a pseudo-immature status in which the molecular
properties partially resemble those in the normal immature brain. However, genome-wide gene expression patterns in
the brains of patients with schizophrenia and those of normal infants have not been directly compared. Here, we show
that the gene expression patterns in the schizophrenic prefrontal cortex (PFC) resemble those in the juvenile PFC.
Results: We conducted a gene expression meta-analysis in which, using microarray data derived from different studies,
altered expression patterns in the dorsolateral PFC (DLFC) of patients with schizophrenia were compared with those in
the DLFC of developing normal human brains, revealing a striking similarity. The results were replicated in a second DLFC
data set and a medial PFC (MFC) data set. We also found that about half of the genes representing the transcriptomic
immaturity of the schizophrenic PFC were developmentally regulated in fast-spiking interneurons, astrocytes, and
oligodendrocytes. Furthermore, to test whether medications, which often confound the results of postmortem
analyses, affect on the juvenile-like gene expressions in the schizophrenic PFC, we compared the gene expression
patterns showing transcriptomic immaturity in the schizophrenic PFC with those in the PFC of rodents treated with
antipsychotic drugs. The results showed no apparent similarities between the two conditions, suggesting that the
juvenile-like gene expression patterns observed in the schizophrenic PFC could not be accounted for by medication
effects. Moreover, the developing human PFC showed a gene expression pattern similar to that of the PFC of naive
Schnurri-2 knockout mice, an animal model of schizophrenia with good face and construct validity. This result also
supports the idea that the transcriptomic immaturity of the schizophrenic PFC is not due to medication effects.
Conclusions: Collectively, our results provide evidence that pseudo-immaturity of the PFC resembling juvenile PFC
may be an endophenotype of schizophrenia.
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Schizophrenia is a devastating and complex brain disorder.
Although many susceptibility genes have been identified
through genome-wide association studies [1-4], each
gene exerts only a small to moderate effect on overall
disease risk. Identifying endophenotypes in the brains of
patients with schizophrenia is now considered the way
to understand the etiology and mechanisms of the* Correspondence: miyakawa@fujita-hu.ac.jp
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unless otherwise stated.disorder. Growing evidence from postmortem [5-9] and
animal studies [10-12] implicates abnormal neurodeve-
lopment in the pathogenesis of schizophrenia and other
psychiatric disorders. We screened >160 mutant mouse
strains using a large-scale comprehensive behavioral test
battery and identified several strains with behavioral
traits corresponding to schizophrenia [13]. We exam-
ined the brains of the latter group using various ap-
proaches and found abnormalities in the dentate gyrus
(DG) of the hippocampus in these mutants. That is, the
molecular and electrophysiological features of DG neu-
rons in the adult hippocampus of these mouse strains
showed similarities to those of immature DG neurons in
normal mice, a phenomenon termed the “immatureal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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http://www.molecularbrain.com/content/7/1/41DG” (iDG). To date, identified mouse strains with an
iDG phenotype include the alpha-calcium/calmodulin-
dependent protein kinase II heterozygous knockout
(HKO) [12], schnurri-2 (Shn-2) KO [11], and mutated
synaptosomal-associated protein 25 (SNAP-25) knock-
in mice [10]. Importantly, postmortem analysis revealed
an iDG-like signature in the brains of patients with
schizophrenia or bipolar disorder [8]. We therefore pro-
posed that the iDG is a potential endophenotype of several
psychiatric disorders, including schizophrenia and bipolar
disorder. The maturation of gamma-aminobutyric acid
(GABA) signaling, characterized by progressive develop-
mental switches in expression from GAD25 to GAD67
and from NKCC1 to KCC2, is abnormal in the hippo-
campus of patients with schizophrenia [6]. In addition
to the hippocampus, we found abnormal development
and maturation in the cortex in a mouse model of
schizophrenia [11]. Abnormalities in development and
maturation have been also implicated in the cortex of
patients with schizophrenia. Risk alleles for schizophrenia
may directly affect PFC development [14,15]. Torkamani
et al. showed that the age-related decline of genes as-
sociated with developmental processes, such as neur-
onal differentiation, neurite outgrowth, and synaptic
transmission, appeared to be slowed in the cortex of pa-
tients with schizophrenia [7]. This suggests that the ex-
pression of a subset of genes in the schizophrenic brain
has become arrested at an adolescent (up to 19 years)
developmental stage [16]. Consistent with this idea, a
hyperdopaminergic state in patients with schizophrenia
has been suggested to resemble the dopamine hyper-
activity in the adolescent brain [17]. In the case of the
GABAA receptor, α1 subunit expression increases dur-
ing PFC development and persists into adulthood,
whereas α2 subunit expression decreases [18,19]. A de-
crease in α1 subunits [18,20,21] and an increase in α2
subunits [21,22] have been found in the schizophrenic
PFC. Changes in GABAA receptor subunits in schizophre-
nia may reflect a cortex held in a state of immaturity
during adulthood. Furthermore, fast-spiking interneurons
(FS neurons) in the cortices of patients with schizophrenia
show maturational abnormalities [5]. Several lines of evi-
dence show that expression levels of parvalbumin (PV), a
marker of FS neurons, are decreased in the PFC of these
patients [23-28]. PV immunoreactivity first appears in
the PFC around 3–6 months of age and PV mRNA in-
creases 20-fold from the neonatal stage to the adulthood
[28,29], indicating that PV is a marker for mature FS neu-
rons. The FS neurons in the cortices of patients with
schizophrenia were hypothesized to be immature [5]. It
was recently shown that, in schizophrenia, this neuron
type retains a pseudo-immature status with regard to
gene expression profiles [5]. Shn-2 KO mice, a mouse
model of schizophrenia with iDG in the hippocampus,showed a decrease in the number of PV-positive cells
in the frontal cortex, without signs of neurodegenera-
tion in either region [11], which suggests that the im-
mature signature can be seen in the mutant mice not
only in the hippocampus but also in the frontal cortex.
In contrast, somatostatin expression, a marker for a
certain interneuron type, decreases from birth in the
normal PFC, but shows a significant decrease in the
schizophrenic PFC [28,30]. Considering that there are
genes with expression patterns that are inconsistent with
an immature phenotype in the schizophrenic PFC, it is
important to evaluate immaturity in the brain using
genome-wide gene expression profiles. However,
genome-wide gene expression patterns in the brains of
patients with schizophrenia and those of normal in-
fants have not been directly compared.
Reports on studies of large-scale gene expression in
various regions of the schizophrenic brain, including
PFC, have been accumulating in publicly available da-
tabases. In this study, we performed bioinformatics
analyses of such data (public microarray data sets) to
see if the maturational state of the PFC is affected in
schizophrenia. We compared genome-wide gene ex-
pression patterns of human developing PFC and adult
schizophrenic PFC using different data sets reported
independently.
Results
Gene expression patterns in the PFC of patients with
schizophrenia resembling those in developing normal
infants
To assess whether, or to what extent, the overall gene
expression profile in the schizophrenic PFC is similar to
that in the developing PFC, we comparatively analyzed
human microarray data sets as follows: development of
the normal dorsolateral frontal cortex (DLFC; GSE13564;
Brodmann’s area [BA]46) compared to the schizophrenic
DLFC (short-DOI subgroup in GSE21138; BA46; Figure 1a).
Microarray data sets were compared using non-parametric
rank-based statistical methods, which incorporates infor-
mation regarding rank and the direction of gene expression
changes into overlap P-values (see Methods section for
details). This schizophrenic DLFC data was obtained by
querying the NextBio database for the curated microarray
data in humans that show gene expression patterns similar
to those for the developing DLFC (<2 years vs. 20–49
years; GSE13564 [31]). We identified a high overlap in
P-values between the schizophrenic DLFC (short-DOI
vs. age-matched control; GSE21138 [32]) and the nor-
mally developing DLFC (P = 6.1 × 10−38, Additional file 1:
Table S1). In addition, we found the intermediate-DOI
(P = 1.1 × 10−16) and long-DOI (P = 0.0002) subgroups
showed less overlap in P-values when compared with
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Figure 1 Comparison of gene expression patterns between the
developing and adult schizophrenic prefrontal cortex (PFC). (a)
The gene expression pattern in the dorsolateral frontal cortex (DLFC;
Brodmann area [BA]46) of patients with schizophrenia (GSE21138,
patients [26.1 ± 2.05 years] compared with controls [28.8 ± 2.55 years])
was compared with that in the DLFC (BA46) of normal infants
(GSE13564, infants <2 years, compared to adults, 20–49 years). (b)
The gene expression pattern in the DLFC (BA46) of patients with
schizophrenia (GSE21138, patients compared with controls) was
compared with that in the DLFC (BA9 and 46) of normal infants
(GSE25219, infants, 1–5 years, compared with adults, 20–39 years).
Note that microarray data sets of the normal developing DLFC were
obtained from two independent research groups and were used in
(a) and (b), respectively. (c) The gene expression pattern in the
medial prefrontal cortex, (MFC) (BA10) of patients with schizophrenia
(GSE17612, patients [73.3 ± 15.2 years] compared with controls
[69.0 ± 21.6 years]) was compared with that in the MFC (BA24, 32, 33)
of normal infants (GSE25219, infants, 1–5 years, compared with adults,
20–39 years).
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with the data from the short-DOI subgroup. By com-
paring these microarray data sets on the developing
and adult schizophrenic DLFC, we found a high degree of
gene expression overlap between them (Figure 2a). Out of
2757 probes altered in the schizophrenic DLFC, 886
were shared with probes altered during the DLFC de-
velopment, indicating statistically significant similarities in
the transcriptome change between them (overlap P-value:
P = 6.1 × 10−38, Figure 2a, Additional file 1: Table S3). Among
the 886 probes, 91 were upregulated (P = 0.053) and 563
were downregulated in both groups (P = 1.0 × 10−75;Figure 2b). These 91 and 563 probes with the same
direction of change in expression between the two
groups are denoted as showing a positive correlation.
We also found that 193 probes were upregulated in the
developing DLFC and downregulated in schizophrenia
(P = 0.197), and 39 probes were downregulated in the
developing DLFC and upregulated in schizophrenia
(P = 0.735; Figure 2b). The probes that showed opposite
changes between the two groups are denoted as showing a
negative correlation. The number of probes with a positive
correlation (654 out of 886 probes) was significantly higher
than expected on the basis of chance (χ2(1) = 201.00,
P = 1.27 × 10−45; Figure 2b). Collectively, these findings
indicate the gene expression patterns in the schizophrenic
DLFC are highly similar to those in the infant DLFC.
To confirm further the results obtained in the schizo-
phrenic DLFC, we repeated the comparative analysis
using different microarray data examining developmen-
tally regulated gene expression in DLFC (Figure 1b).
These microarray data were obtained from a differential
analysis of infants (1–5 years) and adults (20–39 years;
GSE25219 [33]). We found that a large number of
genes overlapped in this comparison as well (578 probes,
P = 8.5 × 10−21, Figure 2c, Additional file 1: Table S4).
Among the 578 overlapped probes, 542 showed a positive
correlation: 29 (P = 7.1 × 10−5) and 513 (P = 4.5 × 10−37)
were upregulated and downregulated in both groups, re-
spectively (Figure 2d). Seven probes were upregulated in
the developing DLFC but downregulated in schizophrenia
(P = 0.915), and 29 probes were downregulated in the devel-
oping DLFC but upregulated in schizophrenia (P = 0.491;
36 probes with negative correlation; Figure 2d). The num-
ber of probes with a positive correlation (542 out of
578 probes) was significantly higher than expected
(χ2(1) = 442.97, P = 2.45 × 10−98; Figure 2d). These find-
ings also indicate that gene expression patterns in the
schizophrenic DLFC are highly similar to those in the
infant DLFC.
To further confirm the transcriptomic immaturity in the
DLFC of patients with schizophrenia, we examined gene
expression patterns in data sets examined in other micro-
array studies. When the gene expression patterns in the
developing DLFC (infants vs. adults; GSE11512 [34]) were
compared with those in the 2 schizophrenia cohorts
(patients vs. controls; GSE53987 or GSE12649 [35]), we
found statistically significant similarities in both compari-
sons (P = 8.4 × 10−22 and P = 1.8 × 10−5; Additional file 2:
Figure S1). Overall, essentially the same results as those
shown in Figure 2a and c were obtained when using the
data sets from the developing DLFC and schizophrenic
DLFC. The result of a high similarity of gene expression
between developing normal DLFC and adult schizophrenic
DLFC was replicated by comparing the schizophrenic
DLFC data with different data for the developing DLFC.
Figure 2 Transcriptional immaturity of PFC in the schizophrenic brain. (a, c, e) Venn diagrams illustrating the overlap in transcriptome-wide
gene expression changes in the DLFC (BA46) of patients with schizophrenia (patients compared with controls) and normal infants (infants <2 years,
compared with adults, 20–49 years) (a), the DLFC (BA46) of patients with schizophrenia (patients compared with controls) and that in the DLFC
(BA9 and 46) of normal infants (infants, 1–5 years, compared with adults, 20–39 years) (c), and the MFC (BA10) of patients with schizophrenia
(patients compared with controls) and that in the MFC (BA24, 32, 33) of normal infants (infants, 1–5 years, compared with adults, 20–39 years)
(e). (b, d, f) P-values of overlap between the schizophrenic DLFC and normal developing DLFC (<2 years compared with 20–49 years) data sets
(b), schizophrenic DLFC and normal developing DLFC (1–5 years compared with 20–39 years) data sets (d), and schizophrenic MFC and normal
developing MFC (1–5 years, compared with 20–39 years) data sets (f). Bar graphs illustrate the P-values of overlaps of genes upregulated
(red arrows) or downregulated (blue arrows) by each condition, between the two conditions. Bonferroni correction was used to adjust the
significant level by the number of pairs of datasets included in each study (see the Methods section and Additional file 1: Table S27). The
genes that showed the same directional changes in expression, or positive correlation, between two groups in (b), (d), and (f) were designated Bioset1–3
(surrounded by dotted line), respectively. These Biosets were used in the analyses for pathway enrichment (Additional file 1: Table S6, S7, S9)
and cell-type contribution (Figure 3).
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terns in another part of the frontal lobe using microarray
data on the developing normal MFC and adult schizo-
phrenic MFC (Figure 1c). When we used a NextBio ana-
lysis to compare the gene expression patterns in the
schizophrenic MFC (GSE17612 [36]) with those in the
developing normal MFC (GSE25219 [33]), we found sta-
tistically significant similarities in the transcriptome
change patterns between the data sets (P = 2.6 × 10−8,Figure 2e, Additional file 1: Table S5). Out of the 225
probes overlapped between the 2 groups (Figure 2e,
Additional file 1: Table S5), 184 showed a positive cor-
relation within 2 groups, which was significantly higher
than expected (χ2(1) = 90.88, P = 1.52 × 10−21, Figure 2f ).
This also indicated that the gene expression patterns in
the schizophrenic MFC are similar to those in the infant
MFC. The subjects chosen by Maycox et al. had an
average age of 70 years [36]. In a comparative analysis
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group in the developmental data set, we also found similar-
ity between the two data sets (P = 0.0053, Additional file 3:
Figure S2). Considering this result and the data shown in
Figure 2, the gene expression pattern in the MFC of pa-
tients with schizophrenia may be similar to that of infants.
Taken together, the results of the analyses in DLFC
and MFC showed similar trends, providing evidence that
whole-tissue gene expression patterns in the PFC of pa-
tients with schizophrenia resemble those of infants. The
genes showing positive correlations in the two analyses forFigure 3 Cell-type contributions to transcriptional immaturity in schiz
expression between the normal developing and adult schizophrenic PFC (a
i-l, Bioset3 in MFC data set) were compared to those obtained from cell-ty
b, f, j, astrocytes [GSE9566]; c, g, k, oligodendrocytes [GSE9566]). Venn diag
changes between two conditions. Bonferroni correction was used to adjus
each study (see the Methods section and Additional file 1: Table S27). Bar gra
or downregulated (blue arrows) by each condition, between the two con
i–k. (d, h, l) Pie chart representing the percentage that each cell-type co
Bioset3 (l). Ast, astrocytes; FS, FS neurons; OL, oligodendrocytes.DLFC (Figure 2b, d) and in the analysis for MFC (Figure 2f)
were designated Bioset1–3, respectively. These Biosets
were used in the pathway analysis (Additional file 1: Table
S6, S7, S9) and cell-type contribution analysis (Figure 3).
Enriched pathways in juvenile-like PFC of patients with
schizophrenia
We analyzed the gene list (all genes in Biosets 1–3) for en-
richment of gene ontology (GO) and canonical pathways
using DAVID bioinformatics databases (Additional file 1:
Table S6). Significantly enriched (Benjamini-adjustedophrenic PFC. Genes showing the same directional changes in
-d, Bioset1 in DLFC data set; e-h, Bioset2 in second DLFC data set;
pe specific developmental experiments (a, e, i, FS neurons [GSE17806];
rams illustrate the overlap in transcriptome-wide gene expression
t the significant level by the number of pairs of datasets included in
phs illustrate the P-values of overlaps of genes upregulated (red arrows)
ditions. Note that the scale of the y-axis is the same in a–c, e–g, and
ntributes to altered gene expression in Bioset1 (d), Bioset2 (h), and
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that changed in both the developing normal PFC and
adult schizophrenic PFC with a positive correlation
(Biosets 1–3) are presented in Additional file 1: Table S6.
In addition, we examined the enriched pathways in each
Bioset using NextBio (Additional file 1: Table S7). The
top 30 enriched pathways are listed in Additional file 1:
Table S7, ranked according to their enrichment score;
the score is based on the overall statistical significance
and consistency of the enrichment, or overlap, between
the genes that make up the pathway involved and each
Bioset queried. In analyses using both DAVID and
NextBio, we found statistically significant enrichments for
pathways related to mitochondrial components, vacuolar
components, and bacterial infection in these Biosets
(Additional file 1: Table S6, S7). A pathway analysis using
DAVID (without multiple comparison correction) for the
22 transcripts, which overlapped among three Biosets
(Additional file 4: Figure S3, Additional file 1: Table S8),
showed enrichments in pathways related to energy metab-
olism (Additional file 1: Table S9).
Cell type contributions to transcriptional immaturity of
PFC in patients with schizophrenia
Next, we determined which cell types contribute to the
juvenile-like gene expression patterns in the schizophrenic
PFC. Because there is no human microarray data on the
development of specific cell types, we used mouse data on
the development of FS neurons [37], astrocytes, and oligo-
dendrocytes [38] for assessing cell type contributions. We
estimated the contribution of each cell type by comparing
2 groups: genes altered in both the normal developing
human PFC and adult schizophrenic PFC with the
same directional change in expression, and those devel-
opmentally regulated in particular cell types.
The microarray data on FS neurons were obtained from
GFP-expressing neurons isolated by cell sorter from
transgenic mice expressing GFP under the control of
the GAD1 promoter at postnatal days (P) 7–40 [37].
The transgenic mice were engineered by the genomic
incorporation of a 200 kb GAD1 bacterial artificial
chromosome fused to a GFP coding sequence. The
combination of the promoter and position of integration
effects restricted GFP expression to a homogenous sub-
set of GABAergic FS neurons. GAD1 promoter-driven
GFP expression is a stable marker for prospective FS
PV-positive cortical interneurons during development
in this mouse line [37]. Data from P40 and P7 of the FS
neurons were compared, and the result was taken as a
sample of the developmental gene expression changes
of this cell type in this study (Table 1). GFP-positive as-
trocytes, which were collected by cell sorter from S100β
(a marker of astrocyte)-GFP transgenic mice at P1–30,
were processed for microarray analysis [38], and we usedthese data to sample the developmental gene expression
changes of astrocytes by comparing P17–30 with P1–8
(Table 1). The oligodendrocytes were purified by antibody-
based panning methods using antibodies against matur-
ational markers (PDGFRα, GalC, and MOG) expressed
by mice at P16, and were then processed for microarray
analysis [38]. We compared the microarray data from
MOG-positive myelinating oligodendrocytes with GalC-
positive premyelinating oligodendrocytes, and used the
result as a sample of the developmental gene expression
changes of oligodendrocytes. The differences in the
methods used for cell collection and in the ranges of
maturational time points of each cell type should be
taken into account when directly comparing the extent
of contribution among these cell types.
Of 561 genes in Bioset1, which consists of genes with
expression changes in both human developing DLFC
and schizophrenic DLFC with a positive correlation, 210
genes (37.4%) were shared with data sets reflecting mouse
FS neuron development (overlap P-value: P = 2.6 × 10−12;
Figure 3a, Additional file 1: Table S10). Furthermore,
it was found that 94 genes (16.8%) and 161 genes
(28.7%) were overlapped between Bioset1 and data
sets of astrocyte development (P = 0.014; Figure 3b,
Additional file 1: Table S11) and oligodendrocyte de-
velopment (P = 3.0 × 10−11; Figure 3c, Additional file 1:
Table S12), respectively. Importantly, most of the genes
commonly changed in Bioset1 and in the development of
each cell type showed the same directional change in ex-
pression: a positive correlation (179 out of 210 genes in
comparison with FS neuron development, χ2(1) = 104.30,
P = 1.73 × 10−24, Figure 3a; 62 out of 94 genes in astrocytes,
χ2(1) = 9.57, P = 1.97 × 10−3, Figure 3b; and 116 out of 161
genes in oligodendrocytes, χ2(1) = 31.31, P = 2.20 × 10−8,
Figure 3c). In addition, among these 561 genes, 101
(18.0%), 23 (4.1%) or 59 genes (10.5%) showed significant
changes developmentally only in mouse FS neurons,
astrocytes, or oligodendrocytes, respectively (Figure 3d,
Additional file 1: Table S13). Twenty-six (4.6%), 57
(10.2%), and 19 genes (3.4%) were shared between FS neu-
rons and astrocytes, FS neurons and oligodendrocytes, and
astrocytes and oligodendrocytes, respectively. Twenty-six
(4.6%) out of 561 genes in Bioset1 showed developmental
regulation commonly in these three cell types (Figure 3d).
On the whole, 311 out of 561 genes (55.4%), representing
juvenile-like expression patterns in schizophrenic DLFC,
could be explained as representing transcriptional imma-
turity in just these three cell types (Figure 3d).
Furthermore, we observed similar trends in the results
regarding cell-type contributions to the juvenile-like
gene expressions in Bioset2 (a second data set for
DLFC; Figure 3e–h) and in Bioset3 (a data set for MFC;
Figure 3i–l). In comparisons using Bioset2, the expression
of 197, 107, and 168 genes were overlapped with data sets





Samples No. of samples




Dorsolateral prefrontal cortex (BA46) of infants (0−2 yr)
and adults (20-49 yr)
Infants = 18, adults = 13




Dorsolateral prefrontal cortex (BA9, 46) of infants (1-5 yr)
and adults (20-39 yr); medial prefrontal cortex (BA24, 32, 33)
of infants (1-5 yr) and adults (20-39 yr); superior temporal
cortex of infants (0−5 yr) and adults (20-39 yr)
DLFC: infants =6, adults =14; MFC: infants = 5,
adults = 14; STC: infaints =7, adults = 13




Dorsolateral prefrontal cortex of infants (0.1-0.3 yr) and
adults (20-49 yr)
Infants = 7, adults = 11




Superior temporal cortex of infants (0−6 yr) and
adults (24-48 yr)
Infants = 7, adults = 5




Prefrontal cortex (BA46) of schizophrenia
(26.1 ± 2.1 yr) and control (28.8 ± 2.6 yr) subjects
SZ = 8, CTL = 7




Prefrontal cortex (BA46) of schizophrenia (42.6 ± 8.5 yr)
and control (44.1 ± 7.7 yr) subjects
SZ = 35, CTL = 34




Prefrontal cortex (BA46) of schizophrenia (46.0 ± 8.6 yr)
and control (48.1 ± 7.6 yr) subjects
SZ = 15, CTL = 19




Anterior prefrontal cortex (BA10) of schizophrenia
(73.3 ± 15.2 yr) and control (69.0 ± 21.6 yr) subjects
SZ = 26, CTL =21




Superior temporal cortex (BA22) of schizophrenia
(72.2 ± 16.9 yr) and control (67.7 ± 22.2 yr) subjects
SZ = 23, CTL = 19
GSE17806 Okaty et al.,
2009 [37]
Mouse430.2.0 Fast-spiking interneurons isolated from somatosensory
cortex of P7 and P40 mice
P7 = 3, P40 = 3
GSE9566 Cahoy et al.,
2008 [38]
Mouse430.2.0 Astrocytes isolated from forebrain of P1-30 mice and
oligodendrocytes isolated based on maturation markers
expression from forebrain of P16 mice
Ast: P1-8 = 4, P17-30 = 4; OL: OL = 4,
Myelin OL = 4
GSE4675 Semeralul et
al., 2006 [96]
Mouse430A.2.0 Whole frontal cortex of 2 and 10 weeks old mice 2 weeks old = 6, 10 weeks old = 4
GSE42775 Takao et al.,
2013 [11]
Mouse430.2.0 Medial frontal cortex of Schnurri-2 KO and wild-type mice KO = 6, WT = 6
GSE45229 Kondo et al.,
2013 [97]
Mouse430.20 Frontal cortex of mice treated with haloperidol,
quetiapine, or a vehicle
Haloperidol (0.3 mg/kg) = 4; Haloperidol
(1 mg/kg) = 4; Quetiapine (10 mg/kg) = 4;
Quetiapine (100 mg/kg) = 4; Vehicle = 4
GSE2547 Fatemi et al.,
2006 [98]
Rat430.2.0 Frontal cortex of rats treated with olanzapine or vehicle Olanzapine (2 mg/kg) = 20, vehicle = 20
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Additional file 1: Table S14), astrocyte development
(P = 0.0086, Figure 3f, Additional file 1: Table S15),
and oligodendrocyte development (P = 2.3 × 10−5, Figure 3g,
Additional file 1: Table S16), respectively. The expression
of 164 out of 197 genes (χ2(1) = 87.11, P = 1.03 × 10−20,
Figure 3e), 67 out of 107 genes (χ2(1) = 6.81, P = 0.0091,
Figure 3f), and 98 out of 168 gens (χ2(1) = 4.67, P = 0.031,
Figure 3g) showed a positive correlation in each com-
parison. In comparisons with Bioset3, the expression
of 68, 44, and 65 genes were overlapped in data sets
from FS neuron (P = 5.0 × 10−4, Figure 3i, Additional file 1:
Table S18), astrocyte (P = 0.107, Figure 3j, Additional file 1:
Table S19), and oligodendrocyte development (P = 0.023,
Figure 3i, Additional file 1: Table S20), respectively.
The expression of 57 out of 68 genes (χ2(1) = 31.12,
P = 2.43 × 10−8, Figure 3i) and 26 out of 44 genes
(χ2(1) = 1.45, P = 0.228, Figure 3j) showed positivecorrelations in comparisons with FS neuron and astro-
cyte development, respectively. In contrast, 43 out of
65 genes showed negative correlations in comparison
with oligodendrocyte development (χ2(1) = 6.78, P = 0.0092,
Figure 3k), suggesting putatively elevated maturation
of oligodendrocytes in the MFC of patients with
schizophrenia.
Transcriptional immaturity of PFC in an animal model of
schizophrenia but not in rodents treated with antipsychotics
Most patients diagnosed with schizophrenia are medicated
with antipsychotics. Consequently, juvenile-like gene
expression patterns observed in the schizophrenic PFC
could result from medications. We therefore tested
whether antipsychotic treatments induce transcriptomic
immaturity in PFC by comparing gene expression pat-
terns in the PFC of rodent treated with antipsychotics
(haloperidol, quetiapine [GSE45229], or olanzapine
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analyses revealed no apparent similarities between the
given two conditions, except for a comparison between
olanzapine-treated rodent PFC and the human developing
MFC (Additional file 5: Figure S4). Similarity between the
olanzapine-treated rodent PFC and the human developing
MFC was weakly but marginally significant after Bonferroni
correction (significance level of P < 0.0125; Additional
file 5: Figure S4o; see the Methods section and Additional
file 1: Table S27), suggesting that olanzapine may have
some effect on the induction of juvenile-like gene expres-
sion in adult PFC.
Furthermore, we tested a mouse strain that models
schizophrenia, that had no history of drug treatment, for
evidence of immaturity in the PFC. The disease-associated
part of the gene expression pattern in the MFC of the
mouse schizophrenia model, Shn-2 KO mice (deduced as
Shn-2 KO compared with wild-type, GSE42775 [11]), was
compared with the developmentally-related part of the
expression pattern deduced to exist in the MFC (BA24,
32, and 33) of human infants (infants, 1–5 years, com-
pared with adults, 20–39 years, GSE25219 [33]). Shn-2,
a nuclear factor-κB site-binding protein, binds to the
enhancers of major histocompatibility complex class I
genes and inflammatory cytokines, which harbor common
variant single-nucleotide polymorphisms associated with
schizophrenia [3,39,40]. Shn-2 KO mice display behavioral
abnormalities that resemble the symptoms of human
schizophrenia, including working memory deficits and
decreased social behaviors [11]. Moreover, the brains of
Shn-2 KO mice have numerous schizophrenia-related
phenotypes, such as transcriptome/proteome changes
similar to those of postmortem patients with schizophre-
nia, decreased PV and GAD67 levels, increased theta and
decreased gamma power on electroencephalograms, and a
thinner cortex [11,41-44]. Thus, Shn-2 KO mice serve
as an animal model of schizophrenia with good face and
construct validity. Recently, de novo damaging muta-
tions were detected in the schizophrenic PFC in the gene
encoding Shn-1 (also called Hivep1), another member of
the Schnurri family, which was suggested to be involved
in pathways important for brain development [14]. Using
microarray data on MFC of Shn-2 KO mice, we investi-
gated whether the mouse model of schizophrenia has
transcriptional immaturity in the PFC. Both MFC of hu-
man and MFC of rodents receive projections from the
medial part of the mediodorsal nucleus of the thalamus
[45], which suggests the mouse MFC is the counterpart of
the human MFC. One hundred and 10 genes overlapped
between human developing MFC and Shn-2 KO mice
MFC, indicating significant similarities in the pattern of
transcriptome changes between the two groups (P = 0.0063,
Figure 4a, Additional file 1: Table S22). Of those genes,
70 showed the same directional changes in expression(Figure 4b), and of these genes, 55 were downregulated
(P = 2.5 × 10−5) whereas 15 were upregulated (P = 0.222).
To determine what cell type contributes to this transcrip-
tome change, 70 genes that showed a positive correl-
ation (Bioset4) were compared with data sets from cell
type-specific developmental experiments (Figure 4c-e).
The expression of 22 genes was changed in common be-
tween Bioset4 and the data set for FS neuron devel-
opment (P = 9.0 × 10−4, Figure 4c, Additional file 1:
Table S23). Between Bioset4 and the data set for
astrocyte development, only nine genes changed in com-
mon (P = 0.411, Figure 4d, Additional file 1: Table S24).
Although 21 genes were differentially expressed in parallel
between Bioset4 and the oligodendrocytes development
data set (P = 0.136, Figure 4e, Additional file 1: Table S25),
more than half of those genes were regulated in the
opposite direction. Of the 70 genes in Bioset4, 20
(28.6%) were regulated similarly in immature FS neu-
rons (Figure 4f, Additional file 1: Table S26). These
results suggest that the gene expression pattern of FS
neurons in the PFC of Shn-2 KO mice resembles that
of immature FS neurons.
Discussion
In this study, we show that the schizophrenic PFC re-
sembles the juvenile PFC with respect to transcriptome-
wide gene expression profiles. We compared relative gene
expression in the DLFC and MFC of patients with schizo-
phrenia (patients compared with controls) with that in cor-
responding regions of the human developing PFC
(infants compared with adults), and showed striking
similarities between them. Moreover, we revealed that
transcriptional immaturity could be seen in multiple cell
types in the schizophrenic PFC, including FS neurons,
astrocytes, and oligodendrocytes. Our findings support
the idea that immaturity in the PFC could be an endo-
phenotype of schizophrenia.
Regarding gene expression, our bioinformatics analyses
revealed highly significant similarities in the relative gene
expression patterns in the PFC between patients with
schizophrenia (as compared to healthy controls) and in-
fants (as compared to adults). More specifically, the ex-
pression level of a large number of genes that normally
increases during human DLFC development was de-
creased in the DLFC of patients with schizophrenia
(Figure 2b). In other words, these genes can be consid-
ered maturation markers whose expression is disturbed
in the DLFC of patients with schizophrenia. The similar-
ity in the maturation marker expression patterns and those
of schizophrenia markers in adults was extraordinary sig-
nificant, and the result was replicated in 3 further analyses
using other two DLFC data sets and an MFC data set,
respectively (Figure 2d, f, Additional file 2: Figure S1b).
Genes for immaturity markers with expression that
Figure 4 Transcriptional immaturity of PFC in an animal model of schizophrenia. (a) Venn diagram illustrating the overlap in transcriptome-wide
gene expression changes in the MFC of Shn-2 KO mice (Shn-2 KO compared to wild type) and that in human infants (GSE25219; infants, 1–5 years,
compared with adults, 20–39 years). (b) P-values of overlap between Shn-2 KO mouse and human infant data sets. Bar graph illustrates the
P-values of overlaps of genes upregulated (red arrows) or downregulated (blue arrows) by each condition, between the two conditions.
The genes that showed the same directional changes in expression, or positive correlation, between two groups were designated Bioset4.
(c–e) Comparison of gene expression derived from cell-type specific developmental experiments (c, FS neurons [GSE17806]; (d), astrocytes
[GSE9566]; (e), oligodendrocytes [GSE9566]) with Bioset4. Bonferroni correction was used to adjust the significant level by the number of
pairs of datasets included in each study (see the Methods section and Additional file 1: Table S27). (f) Pie chart representing the percentage
that a particular cell type contributes to the altered gene expression pattern in Bioset4.
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in the PFC of patients with schizophrenia, but to a
lesser extent. Thus, the transcriptional immaturity of
the schizophrenic PFC could be characterized as prefer-
ential downregulation of maturation marker gene expres-
sion. When the gene expression patterns in the developing
DLFC (infants vs. adults; GSE11512 [34]) were compared
with those in the 2 schizophrenia cohorts (patients vs. con-
trols; GSE53987 or GSE12649 [35]), we found statistically
significant similarities in both comparisons (P = 8.4 × 10−22
and P = 1.8 × 10−5; Additional file 2: Figure S1). The
relatively low overlap P-value in Additional file 2:
Figure S1c relative to other comparisons (Figure 2a, 2c,
Additional file 2: Figure S1a) may be due to the small
number of transcripts that were changed in the patients in
the GSE12649 study [35]. Transcript expression changes
numbering 2757 (806 upregulated and 1951 downregu-
lated), 1163 (529 upregulated and 634 downregulated) and
163 (118 upregulated and 45 downregulated) were found
in the studies GSE21138 [32], GSE53987, and GSE12649
[35], respectively. The differences in the number of tran-
scripts detected in these studies are probably due to differ-
ences in the types of microarray chip that they used(Table 1). The small number of transcripts (45) downregu-
lated in the patients in the GSE12649 study [35] may
have caused the small number of maturation markers
that downregulated in these patients (13 transcripts in
Additional file 2: Figure S1d). Functionally, a deficit in
working memory is common in patients with schizophre-
nia and has been attributed to PFC dysfunction [46].
When the developmental changes in working memory
capacity were tested in normal subjects, 8- to 12-year-olds
performed more poorly than adolescents or adults (age
groups 13–17 and 18–25, respectively) [47]. Together with
these previous results, our results suggest the PFC in
patients with schizophrenia resembles the PFC in normal
infants, both functionally and in gene expression patterns.
In the study by Maycox et al., the MFC analysis was
performed for subjects with schizophrenia and controls
who had an average age of 70 years. In the present study,
we compared the gene expression changes in the MFC
of elderly subjects with schizophrenia (patients vs. con-
trols) with those in the developing MFC (infants vs. rela-
tively young adults [20–39 years]; Figure 1C), which
revealed significant similarities between the two groups
(P = 2.6 × 10−8; Figure 2e). This result might indicate
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define transcriptomic infancy can also be seen in a co-
hort of elderly subjects with schizophrenia. We also
found that gene expression patterns in the schizophrenic
MFC are similar to those in the normal infant MFC as
compared to elderly adult MFC (Additional file 3: Figure
S2), suggesting that both the DLFC and MFC of patients
with schizophrenia represent juvenile-like gene expres-
sion profiles. In addition, we found a significant similarity
in the gene expression patterns of the superior temporal
cortex (STC) between normal infants and patients with
schizophrenia (Additional file 6: Figure S5). These findings
suggest that juvenile-like gene expression profiles also can
be found in brain regions other than the PFC in patients
with schizophrenia.
Our present results also show that juvenile-like gene ex-
pression in the PFC of patients with schizophrenia could
be due to immaturity in multiple cell types, including FS
neurons, astrocytes, and oligodendrocytes. In the case of
immaturity in FS neurons and oligodendrocytes, our re-
sults are consistent with those of previous studies analyz-
ing molecular expression or structures in these cell types
in schizophrenia [5,48]. Dysregulated gene expression in
GABAergic neurons is one of the most robust findings in
schizophrenia neuropathology. It is also a well-replicated
finding that expression of PV, a marker for FS neurons, is
decreased in the PFC of patients with schizophrenia [49].
Considering that PV expression appears in the PFC only
postnatally and drastically increases with age [28,29],
PV is thought to be a marker for mature FS neurons.
Therefore, FS cells were hypothesized to be immature
in schizophrenia [5]. In this context, Gandal et al. deve-
loped an FS cell maturation index to evaluate maturity
of FS neurons in the cortices of patients with psychiatric
disorders including schizophrenia, bipolar disorder, and
autism [5]. Using time-course gene expression data from
developing FS cells that were positively correlated with PV
expression levels, Gandal et al. showed a reduction of the
index in cortices of patients with schizophrenia, bipolar
disorder, and autism. In addition, a decrease in perineuro-
nal nets (PNNs) has been reported in the schizophrenic
PFC [50]. Considering that PNNs are extracellular matrices
predominantly enriched around mature FS neurons [51],
their decrease may imply the presence of pseudo-immature
FS neurons in schizophrenic cortices. These results suggest
that FS neurons stay at partially immature state in the
cortices of patients with schizophrenia, which is consis-
tent with our results.
Possible contributions of myelin and oligodendrocyte
dysfunction to schizophrenia also have been suggested
by many postmortem studies of the human brain at
molecular [48] and ultrastructural levels [52]. This well-
documented evidence for dysmyelination seems consistent
with our finding of immaturity in oligodendrocytes.Specific markers identify the different stages of oligoden-
drocytes maturation: PDGFRα in oligodendrocyte pro-
genitor cells, GalC in premyelinating oligodendrocytes,
and MOG in myelinating oligodendrocytes. We used the
data set for gene expression changes between premyelinat-
ing and myelinating mouse oligodendrocytes, which were
purified based on maturation marker expression, as an
index for oligodendrocyte immaturity in the present study
[38]. The gene expression changes during oligodendrocyte
maturation showed a significant positive correlation with
those shared by the human developing and schizophrenic
DLFC, suggesting immaturity of oligodendrocytes in the
DLFC of patients with schizophrenia.
In addition to the previous studies suggesting abnormal
maturational status of FS neurons and oligodendrocytes in
the schizophrenic brain, we showed that immaturity of
astrocytes could also be seen in schizophrenic brains. Pos-
sible observations of changes in astrocyte densities in the
cortices of schizophrenia patients are controversial; how-
ever, previous studies have shown the expression of sev-
eral astrocyte-related genes is abnormal in these patients
[52]. For example, increased expression of GLT-1, a major
glutamate transporter, has been reported in the PFC of pa-
tients with schizophrenia [53]. Considering the expression
of GLT-1 in rat astrocytes declines as they mature [54],
the increased GLT-1 expression in the schizophrenic PFC
may imply the existence of astrocytes that partially resem-
ble those in the immature brain. Such immaturity would
support the idea that astrocyte function is linked to the
pathophysiology of schizophrenia.
One might expect that, in patients with schizophrenia, a
decreased expression of a large number of maturation
marker genes might reflect the loss of cells expressing those
genes (i.e., PV in FS neurons and MOG in oligodendro-
cytes). In one study, there was no significant change in the
number of PV-expressing cells in the PFC of patients with
schizophrenia, whereas the PV expression per cell de-
creased when compared with controls [25]. The number
of astrocytes between the schizophrenic and control
PFC also were not significantly different [55-57], even
though expression of astrocyte-related genes is altered
in the cortex of patients with schizophrenia [52,58].
Analyses of oligodendrocytes suggest that subtle oligo-
dendrocyte or myelin anomalies, such as myelin sheath
damage and a decreased mitochondria density [59], may
be more important than the changes in cell density as-
sociated with the pathophysiology of schizophrenia [60].
In the frontal cortex of Shn-2 KO mice, no obvious hall-
marks of neurodegeneration, including cell death, cell
swelling, protein deposition, or nuclear condensation,
were observed with immunohistological or electron
microscopic analyses. The number of PV-positive cells
was significantly reduced in the frontal cortex of Shn-2
KO mice when compared with controls [11]. This
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undetectable levels in the mutant mice, which is similar
to the pathology of schizophrenia in humans. Thus, in
the cortex of patients with schizophrenia, a lower gene
expression may reflect changes in gene expression in
these cell types, rather than cell death.
Recent studies suggest that certain cell types in several
brain regions of patients with schizophrenia may exhibit
maturation abnormalities. By assessing the expression
levels of maturational markers, Walton et al. showed that
the dentate granule cells of the patients may be persist-
ently in pseudo-immature state [8]. Expression of PV is
decreased not only in the PFC but also in the hippocam-
pus of patients with schizophrenia [61]. Furthermore, a
decrease in PNNs has been reported in the entorhinal cor-
tex and amygdala of patients [51,62]. The decreases in PV
and PNNs imply that FS neurons in those brain regions
stay at pseudo-immature state. Expression of KCC2, a
K+-Cl− cotransporter that plays a role in GABAergic neuro-
transmission, is decreased in the PFC and hippocampus of
the patients [6,63]. Considering that KCC2 expression
rises as brain development progresses [64], the decreases
indicate a pseudo-immature state in a certain type of
neuron in the PFC and the hippocampus. In addition,
we observed transcriptomic immaturity in the superior
temporal cortex (STC) of the patients (Additional file 6:
Figure S5). These findings suggest that maturational ab-
normalities can be seen in certain cell types in several
regions across the brain of patients with schizophrenia.
Although we showed that about half of the genes
representing juvenile-like expression patterns in the
schizophrenic PFC were developmentally regulated in
three cell types (Figure 3d, h, l), there is also a possibility
that these altered expression signals are partly due to
maturational abnormalities in other cell types. Gene ex-
pression patterns representing transcriptomic immatur-
ity in the schizophrenic PFC (Bioset 1, 2, and 3) were
similar to those in entire frontal cortex of developing
mice (Additional file 7: Figure S6). Considering that pyr-
amidal neurons are the major population in the cortex
[65], maturational abnormality of this cell type would
contribute to transcriptomic immaturity in the schizo-
phrenic PFC. Glutaminase is specifically expressed in pyr-
amidal neurons [66] and expression increases during
development in human PFC (Additional file 1: Table S8),
suggesting that this gene may be a maker for mature
pyramidal neurons. The gene was found in all Biosets
(Additional file 1: Table S8). This result raises the possi-
bility that pyramidal neurons are also in the immature-
like state in the schizophrenic PFC. To examine this
question, data on developmental gene expression changes
of specific cell types, such as pyramidal neurons,
GABAergic neurons other than FS neurons, and microglia,
are needed.Important issues remain to be resolved: how and when
the maturational abnormality phenomena emerge in the
brains of patients with schizophrenia. Our results indicating
the immaturity of multiple cell types in the schizophrenic
PFC indicate three possibilities for how such immaturity
might occur: failure in cell maturation, reversal of a once-
established cell maturation, or recruitment of immature
cells. The development and maturation of the brain has
long been believed to be a one-way process. However,
growing evidence suggests the maturational state is reg-
ulated bidirectionally for some cell types in adult brains.
Established maturation of granule cells in hippocampal
DG can be reversed by chronic treatment with the select-
ive serotonin reuptake inhibitor fluoxetine, which is widely
used as an antidepressant [67,68], and by the induction of
spontaneous recurrent seizures [69]. Mutation of Shn-2
[11] and SNAP-25 [10] may also reverse the maturational
state of DG granule cells postnatally. In the DG of Shn-2
KO mice, 2-week-old animals showed no significant dif-
ferences between genotypes in the expression of calbindin,
a marker of mature granule cells, or calretinin, a marker
of immature granule cells. Calbindin expression was de-
creased and calretinin expression was increased in the DG
of 4-week-old Shn-2 KO mice compared with that of wild-
type mice, thus indicating that an iDG phenotype emerged
during postnatal development [11]. In SNAP-25 KI mice, it
was suggested that an iDG phenotype is caused by epileptic
seizures that occur after P21–25 [10]. As for FS neurons,
fluoxetine treatment induces an immature-like state in the
visual cortex [70], basolateral amygdala, hippocampus [71],
and the PFC [72] in adulthood. Recently, it was shown that
experience could reverse the differentiation state of FS neu-
rons in the adult hippocampus, as monitored by PV expres-
sion levels, and the consequent plasticity may influence
learning ability [73]. Considering several environmental and
genetic factors can induce a reversal in maturational status
in these neuron types, it is possible that the immaturity of
FS neurons in the schizophrenic PFC represents reversal
of the maturational state. Demyelination induced by cupri-
zone, which could possibly be a partial dematuration of
oligodendrocytes, was shown to cause schizophrenia-like
symptoms in adult rodents [74], suggesting that reversal
of oligodendrocyte maturation may participate in the
pathophysiology of schizophrenia.
The third possibility that might explain the transcrip-
tional immaturity of the schizophrenic PFC is adult cor-
tical neurogenesis. New neurons are generated in the
cortex of adult rodents and primates under pathological
conditions, including ischemia and chemical neurodegen-
eration [75-78]. Considering that elevated inflammatory
conditions have been reported in the cortex of patients with
schizophrenia [79], adult neurogenesis might be increased
in the schizophrenic cortex [80,81]. A recent study demon-
strated that the density of GABAergic interneurons
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[82], which suggests that new neurons might be gener-
ated or recruited in the white matter of patients with
schizophrenia. However, neurogenesis is upregulated by less
than 1% of the total neuron count in the adult cortex under
pathological conditions, such as focal or global ischemia,
cortical tissue aspiration, or a laser-induced lesion [83], sug-
gesting that newly generated neurons can hardly account
for the transcriptional immaturity of the schizophrenic
PFC, even under pathological conditions. Although cor-
tical adult neurogenesis cannot be excluded as a possible
contributory factor, it might not be a major factor.
Some studies have addressed the issue of when the
maturational abnormality phenomena emerge in the
schizophrenic PFC. If the phenomena reflect the con-
sequences of illness chronicity, the magnitude of the al-
terations would be expected to correlate with illness
duration. However, it has been shown that neither ill-
ness duration nor age explain the expression levels of
some genes related to GABAergic neurons, which are
decreased in the schizophrenic PFC, suggesting that the
gene expression changes in schizophrenia are not a con-
sequence of illness chronicity [84]. It has also been
shown that normal age-related decreases in expression of
genes related to central nervous system developmental sys-
tems do not occur in patients with schizophrenia during
the aging process [7], suggesting that disturbances in gene
regulatory mechanisms appear before clinical onset or at
an early stage of clinical illness. In the present study, we
compared data sets from the DLFC of patients with schizo-
phrenia, who were grouped according to age (defined by
Narayan et al. [32]), to the two data sets from the develop-
ing DLFC (developmental data sets in Figure 1a and b).
We found the highest overlap in P-values in comparisons
with the short-DOI schizophrenia group (Additional file 1:
Table S2). Gene expression patterns representing a
juvenile-like phenotype are more likely to be associated
with younger patients than with older patients. Thus,
the altered gene expression that causes abnormalities in
neural maturation in schizophrenia seems to emerge
during postnatal developmental stages prodromally or
concomitantly with clinical onset.
Shn-2 KO mice were previously described as showing
multiple schizophrenia-like phenotypes at molecular,
anatomical, electrophysiological, and behavioral levels
[11]. The transcriptome pattern in the MFC of the Shn-2
KO mice, which we found to be similar to that of human
infant MFC in the present study, is also highly similar to
that from postmortem patients with schizophrenia [11]. In
the present study, we found that genes related to FS
neuron development, rather than oligodendrocyte or as-
trocytes development, showed significant overlap with
genes that are commonly up- or downregulated in the
MFC of Shn-2 KO mice and human infants (Figure 4).Although the altered gene-expression signals linked to the
development of FS neurons may have been derived from
maturational abnormalities in other cell types, pseudo-
immaturity of FS neurons specifically has been suggested
by findings in the MFC of Shn-2 KO mice. We previously
reported a decrease in the number of PV-expressing neu-
rons in the MFC of Shn-2 KO mice [11]. Expression of PV
in FS neurons in the immature brain was quite low (only
one-sixtieth of the adult level) [37], suggesting that the
expression of PV could be undetectable in immature
FS neurons. Thus, the decrease in the number of PV-
expressing neurons in the MFC of Shn-2 KO mice can be
at least partly explained by the immaturity of FS neurons.
The results of postmortem analyses often can be con-
founded by the effects of medications. However, in the
genetically engineered rodent model, we can exclude
the effect of drugs and control other environmental
factors that are not study variables. Therefore, results
showing a significant similarity in gene expression pat-
terns between the human developing MFC and the
Shn-2 KO mouse MFC suggest that the transcriptional
immaturity observed in the schizophrenic PFC may
not be due to medication. We also showed that the
PFC of rodents treated with antipsychotics exhibited
no apparent similarities with the human developing
PFC, except for a comparison between olanzapine-
treated rodent PFC and the human developing MFC
(Additional file 5: Figure S4). These results suggest that
medication effect may not be a major contributing fac-
tor to the transcriptional immaturity found in the
schizophrenic PFC. Other studies also suggest that a
decreased expression of GABAergic neuron-related
genes in the schizophrenic PFC, including PV, seems
unrelated to confounding factors such as medication
or substance use [25,84,85].
To date, many hypotheses have been developed to ex-
plain the mechanisms of schizophrenia. Immaturity of
the PFC seems to be consistent with several major hy-
potheses, such as the neurodevelopmental [9,86], oligo-
dendrocyte [48,87], and inflammation hypotheses
[79,88]. The immaturity of FS neurons literally reflects
a neurodevelopmental problem. Dysfunction of oligo-
dendrocytes characterized by demyelination could be
accounted for by immaturity of oligodendrocytes, as
discussed above. Pathway enrichment analyses showed
that enrichment of inflammation-related pathways is
likely to be accompanied by a juvenile-like PFC pheno-
type (Additional file 1: Table S6, S7). Activation of the
NADPH-oxidase/interleukin-6 (IL-6) pathway, which
is known to play an important role in inflammatory
processes, could increase superoxide production in the
brain and induce a reversible loss of PV-positive cells
in adulthood [89]. In a previous study that used Next
Generation Sequencing Expression, IL-6 mRNA was
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suggesting an increase in inflammation in the schizo-
phrenic PFC [90]. Similarly, oxidative stress increased
significantly in the schizophrenic PFC when compared
with controls [91,92]. These findings suggest that neur-
onal pseudo-immaturity in the PFC could be induced
by brain inflammation, followed by PFC dysfunction,
such as deficits in attention, working memory, and ex-
ecutive functions, which are symptoms of schizophre-
nia. Together, these findings could be a link between
inflammatory conditions and evidence of neuronal
immaturity. Enrichments in energy metabolism- and
mitochondria-related pathways also were found for
genes representing a juvenile-like PFC phenotype
(Additional file 1: Table S6, S7, S9). Energy metabol-
ism mediated by mitochondria plays an important role
in the development and maintenance of mammalian
brains [93]. Because FS neurons have high metabolic
demands and show dramatic upregulation of energy
related genes during development, it has been hypoth-
esized that defects in energy metabolism genes impair
FS neuron development [5]. Thus, enrichments in energy
metabolism-related pathways are likely related to abnor-
malities in cell maturational status, especially in the FS
neurons examined in this study. Taken together, these data
show that a transcriptional immaturity in the PFC can be
considered an endophenotype of schizophrenia, which is
consistent with several etiological hypotheses.
Collectively, our results demonstrate that the genome-
wide expression profile of the schizophrenic PFC re-
sembles that of the juvenile PFC, which could be due
to immaturity in multiple cell types, including FS neu-
rons, astrocytes, and oligodendrocytes. Given that the
pseudo-immature cells, especially FS neurons, are not
actually lost or absent from the schizophrenic PFC,
attempts to restart the normal maturation process
could be a potential therapeutic strategy. Considering
that adult Shn-2 KO mice also have a juvenile-like
PFC, treatments that induce PFC maturation in the
mouse model might be candidate therapies for schizo-
phrenia. For example, chronic administration of anti-
inflammatory drugs lessened the immaturity of the
DG granule cells and some behavioral abnormalities
in Shn-2 KO mice [11]. Further investigation of tran-
scriptional immaturity in the PFC as a factor in the
precipitation of, as well as recovery from, episodes of
schizophrenia would facilitate study of the disorder.
Conclusions
The present study demonstrates that the schizo-
phrenic PFC resembles the juvenile PFC with respect
to transcriptome-wide gene expression profiles. Our
results provide evidence that transcriptomic immaturity of
PFC may be an endophenotype of schizophrenia.Methods
Data and data processing
Fifteen publicly available microarray data sets were used in
this study (Table 1): four data sets on the developing hu-
man cortices (GSE13564 [31], GSE25219 [33], GSE11512
[34], GSE37721 [94]), five on the schizophrenic cortices
(GSE21138 [32], GSE17612 [36], GSE12649 [35],
GSE53987, GSE21935 [95]), two on developing mouse
cortex or cells (GSE17806 [37], GSE9566 [38], GSE4675
[96]), one on the medial frontal cortex (MFC) of the
schizophrenia mouse model Shn-2 KO mice (GSE42775
[11]), and two on the frontal cortices of rodents treated
with antipsychotic drug (GSE45229 [97], GSE2547 [98]).
Patient demographics have been previously described in
detail [32,35,36,95]. In the study by Narayan et al.
(GSE21138) [32], schizophrenic subjects were divided
into three subgroups according to their duration of illness
(DOI), which included a short-DOI, intermediate-DOI,
and long-DOI. The mean ages of these subgroups were
26.1 ± 2.05 (short-DOI), 41.9 ± 3.44 (intermediate-DOI),
and 65.3 ± 2.91 (long-DOI) years. The control groups were
age-matched to their corresponding experimental sub-
group and had mean ages of 28.8 ± 2.55, 41.8 ± 2.47, and
64.6 ± 3.26 years. In the study by Maycox et al.
(GSE17612) [36], the mean ages of schizophrenic and
control subjects were 73.3 ± 15.2 and 69.0 ± 21.6 years,
respectively. In the study by Iwamoto et al. (GSE12649)
[35], the mean ages of schizophrenic and control sub-
jects were 42.6 ± 8.5 and 44.1 ± 7.7 years, respectively.
In the study by Lanz et al. (GSE53987), the mean ages
of schizophrenic and control subjects were 46.0 ± 8.6
and 48.1 ± 7.6 years, respectively. Regarding medications,
most patients chosen by Narayan et al. [32], Maycox et al.
[36], and Iwamoto et al. [35] had been treated with
typical antipsychotic drugs. Information regarding medi-
cations in the study by Lanz et al. is not yet publicly
available.
For the analyses examining the effects of antipsychotic
treatment on transcriptional immaturity, we used micro-
array data from antipsychotic-treated rodent brains,
which were imported to NextBio by the experimenters.
Microarray data from the frontal cortex of mice treated
with haloperidol (0.3 or 1 mg/kg/day, N = 4), quetiapine
(10 or 100 mg/kg/day, N = 4), or a vehicle (N = 4) for
21 days were obtained from the study published by Kondo
et al. [97] (GSE45229). Microarray data from the frontal
cortex of rats treated with olanzapine (2 mg/kg/day, N = 20)
or saline (N = 20) for 21 days were obtained from the
study published by Fatemi et al. [98] (GSE2547).
All microarray data sets were analyzed using NextBio
(http://www.nextbio.com; Cupertino, CA, USA), a data-
base of microarray experiments. NextBio is a repository
of analyzed microarray data sets that allows investigators to
search results and expression profiles. The data registered
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lity control, and curation. Quality assessment methods
are employed to review sample-level and dataset-level
integrity, which includes reviews of pre- and post-
normalization boxplots, missing value counts, and P-
value histograms (after statistical testing) with false-
discovery rate (FDR) analysis to determine whether the
number of significantly changing genes is greater than
that expected by chance. Other processing of micro-
array data is by MAS5 (Affymetrix) [99]. Genes with a
P-value < 0.05 (without correction for multiple testing)
and an absolute fold change >1.2 were used in the data
set of differentially expressed genes. This is typically the
lowest sensitivity threshold used with commercial micro-
array platforms and the default criterion used in analyses
with NextBio. We used Affymetrix GeneChip data se-
lected from the GSE25219 [33], GSE53987, GSE17806
[37], and GSE9566 [38] series, which were downloaded
from the NCBI GEO database. Data was pre-processed
with Affymetrix Expression Console software using the
robust multi-array average algorithm (RMA). Expres-
sion values (on a log base-2 scale) were used to calcu-
late fold changes and P-values between 2 conditions:
young–adults and normal–patients (Table 1). Fold
changes were calculated by dividing the young/disease
value by the adult/normal value. In the supplementary
tables, fold change values are converted into the nega-
tive reciprocal, or −1/(fold change), if the fold change
is less than 1. Genes with |fold change| >1.2 (GSE25219
and GSE53987) or >1.5 (GSE17806 and GSE9566) and a
t-test P-value <0.05 were imported to NextBio accor-
ding to the manufacturer’s instructions. Regarding
GSE13564 [31], GSE11512 [34], GSE37721 [94], GSE21138
[32], GSE17612 [36], GSE12649 [35], GSE21935 [95],
GSE45229 [97], and GSE2547 [98], we used the data
imported into NextBio by the experimenters. Data for
GSE42775 were previous experimental results from our la-
boratory [11] and were imported into NextBio. We com-
pared the signatures in two given gene sets using NextBio.
Overlap between gene sets was calculated using the Running
Fisher test [99]. This non-parametric rank-based statistical
method developed by NextBio enabled us to statistically as-
sess pairwise correlations between any two datasets. Direc-
tional information (up- or downregulation) for each gene
also was incorporated in the analysis to assess the similarities
between datasets.
To enable comparison across different arrays, ortho-
logs were identified for each pair of organisms [99].
Ortholog identification was based on information ob-
tained from Mouse Genome Informatics (MGI) at Jackson
Lab (http://www.informatics.jax.org), HomoloGene at
NCBI (http://www.ncbi.nlm.nih.gov), and Ensembl (http://
www.ensembl.org). The gene overlap P-value calculated
by NextBio indicates a statistically significant associationbetween two given gene sets. The detailed methods for
comparison of data sets are given in Additional file 8. The
significance level of the P-value for overlap between data
sets was corrected for the number of combinations of
data sets (enumerated in Additional file 1: Table S27)
using the Bonferroni method. The level of significance for
overlap in each pair of expression-change directions was
also corrected for the number of possible situations (up,
up; down, down; up, down; down, up) using Bonferroni
method (P < 0.0125 = 0.05/4).
Statistical analysis
Pearson’s chi-square test was applied to the number of
genes with a “positive correlation” or a “negative correl-
ation,” which were compared with the expected fre-
quency of 50%. Significance was defined as a P < 0.05.
Pathway analysis
The DAVID functional annotation clustering tool (david.
abcc.ncifcrf.gov) was used to assess gene lists for enrich-
ment in biological themes [100]. The gene list (all genes
in Biosets 1–3 [Figure 2]) was processed through DAVID
using the default feature listings and algorithm settings,
with the Affymetrix 3′ IVT (Human Genome U133 Plus
2) as a background. P-values from Fisher’s exact tests of
enrichment proportion were Benjamini-adjusted for
multiple testing in DAVID (Additional file 1: Table S6).
We also analyzed for pathway enrichment to find
biogroups for which our gene lists (Bioset 1, 2, and 3)
were highly enriched using NextBio software. We identi-
fied the top 30 biogroups for enrichment score based on
the input gene signature (Additional file 1: Table S7).
Additional files
Additional file 1: Supplementary Tables S1-S27.
Additional file 2: Figure S1. Comparison of gene expression patterns
between the developing and adult schizophrenic DLFC. The gene
expression pattern in the DLFC (BA46) of patients with schizophrenia
(patients compared with controls; GSE53987 [a, b] or GSE12649 [c, d]) was
compared with that in the DLFC (BA46) of normal infants (GSE11512, infants,
0.1–0.3 years, compared with adults 20–49 years). The Venn diagrams
illustrate the overlap in transcriptome-wide gene expression changes in the
DLFC of patients with schizophrenia (patients compared with controls) and
normal infants (infants compared with adults) (a, c). Bar graphs illustrate the
P-values of overlaps of genes upregulated (red arrows) or downregulated
(blue arrows) by each condition, between the two conditions (b, d).
Additional file 3: Figure S2. Comparison of gene expression patterns
between the schizophrenic MFC and the normal infant MFC as compared
to elderly adults. (a) The gene expression pattern in the MFC (BA10)
of patients with schizophrenia (GSE17612, patients [73.3 ± 15.2 years]
compared with controls [69.0 ± 21.6 years]) was compared with that in
the MFC (BA24, 32, 33) of normal infants (GSE25219, infants, 1–5 years,
compared with adults over 60 years). (b) Venn diagrams illustrating the
overlap in transcriptome-wide gene expression changes in the MFC of
patients with schizophrenia (patients compared with controls) and
normal infants (infants, 1–5 years, compared with adults over 60 years).
(c) Bar graphs illustrate the P-values of overlaps of genes upregulated
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two conditions.
Additional file 4: Figure S3. Transcripts overlapped across three Biosets.
The Venn diagram illustrates the extent of overlap across Biosets. Among the
981 probes found in any of the three Biosets, 22 were shared with those
Biosets. The complete gene list is provided in Additional file 1: Table S8.
Additional file 5: Figure S4. Comparison of gene expression patterns
between the human developing PFC and antipsychotic-treated rodent
frontal cortex. (a–e) The gene expression pattern in the DLFC (BA46) of
normal infants (GSE13564, infants <2 years, compared to adults 20–49
years) was compared with that in the frontal cortex of rodents treated
with haloperidol (GSE45229) (a, b), quetiapine (GSE45229) (c, d), or olanzapine
(GSE2547) (e). (f–j) The gene expression pattern in the DLFC (BA9 and 46) of
normal infants (GSE25219, infants, 1–5 years, compared with adults 20–39
years) was compared with that in the frontal cortex of rodents treated with
haloperidol (GSE45229) (f, g), quetiapine (GSE45229) (h, i), or olanzapine
(GSE2547) (j). (k–o) The gene expression pattern in the MFC (BA24, 32, 33) of
normal infants (GSE25219, infants, 1–5 years, compared with adults 20–39
years) was compared with that in the frontal cortex of rodents treated with
haloperidol (GSE45229) (k, l), quetiapine (GSE45229) (m, n), or olanzapine
(GSE2547) (o). Venn diagrams illustrate the overlap in transcriptome-wide gene
expression changes between conditions. Bar graphs illustrate the P-values of
overlaps of genes upregulated (red arrows) or downregulated (blue arrows) by
each condition, between the two conditions. N/A (not applicable) means that
the overlap P-values exceeded the NextBio database cutoff, which is the
default criterion used in analyses by NextBio (a P-value of approximately 0.6).
Additional file 6: Figure S5. Comparison of gene expression patterns
between the developing and schizophrenic STC. The gene expression
pattern in the STC (BA22) of patients with schizophrenia (GSE21935,
patients [72.2 ± 16.9 years] compared with controls [67.7 ± 22.2 years])
was compared with that in the STC of normal infants (GSE25219, infants,
1–5 years, compared with adults 20–39 years) (a–c), or with that in the
STC of normal infants (GSE37721, infants, 2–6 years, compared with
adults 24–48 years) (d–f). (b, e) Venn diagrams illustrating the overlap
in transcriptome-wide gene expression changes in the STC of patients
with schizophrenia (patients compared with controls) and normal infants
(infants compared with adults). (c, f) Bar graphs illustrate the P-values
of overlaps of genes upregulated (red arrows) or downregulated (blue
arrows) by each condition, between the two conditions.
Additional file 7: Figure S6. Comparison of gene expression patterns
between each Bioset and mouse whole frontal cortex development.
Genes showing the same directional changes in expression between the
normal developing and adult schizophrenic PFC (Bioset1 [a, b], Bioset2
[c, d], Bioset3 [e, f], as shown in Figure 2) were compared to those
obtained from developmental experiments on mouse whole frontal
cortex (GSE4675). (a, c, e) Venn diagrams illustrate the overlap in
transcriptome-wide gene expression changes between two conditions.
(b, d, f) Bar graphs illustrate the P-values of overlaps of genes upregulated
(red arrows) or downregulated (blue arrows) by each condition, between the
two conditions.
Additional file 8: Supplementary methods.Abbreviations
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